Chieh‐Hsiang Lu

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 2.8K citations · Full text

Metabolic Syndrome, Diabetes Management, Cardiovascular Disease +9

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 600 citations · Full text

Metabolic Syndrome, Diabetes Management, Urology +10

Efficacy, safety, and tolerability of ipragliflozin in Asian patients with type 2 diabetes mellitus and inadequate glycemic control with metformin: Results of a phase 3 randomized, placebo‐controlled, double‐blind, multicenter trial

Chieh‐Hsiang Lu, Kyung Wan Min, Lee‐Ming Chuang et al. · Journal of Diabetes Investigation · 2015 · 64 citations · Full text

Honokiol, a potential therapeutic agent, induces cell cycle arrest and program cell death in vitro and in vivo in human thyroid cancer cells

Chieh‐Hsiang Lu, Shu‐Hsin Chen, Yi-Sheng Chang et al. · Pharmacological Research · 2016 · 58 citations

Potential Therapeutic Agent, Medicine, Cycle Arrest +8

Reversine, a 2,6-disubstituted Purine, as an Anti-cancer Agent in Differentiated and Undifferentiated Thyroid Cancer Cells

Shih‐Che Hua, Tien‐Chun Chang, Hau‐Ren Chen et al. · Pharmaceutical Research · 2012 · 46 citations

Medicine, Anti-cancer Agent, Thyroid Hormone +5